TOKYO and CAMBRIDGE, Mass., October 31, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the latest findings for lecanemab-irmb (U.S.

东京和马萨诸塞州剑桥，2024年10月31日–卫材株式会社（总部：东京，首席执行官：Haruo Naito，“卫材”）和Biogen Inc.（纳斯达克：BIIB，公司总部：马萨诸塞州剑桥，首席执行官：Christopher A.Viehbacher，“Biogen”）今天宣布，lecanemab irmb（美国。

brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually. Benefits of Continued Treatment with Lecanemab for People with Early ADIn July 2024 at the Alzheimer's Association International Conference (AAIC) 2024, results from the open-label long-term extension study (OLE) following the core study of the lecanemab Phase 3 Clarity AD study were presented, showing that the mean change from baseline in CDR-SB (global cognitive and functional scale) in the lecanemab treated group relative to the placebo group was -0.45 at 18 months, and at 36 months, this expanded to -0.95 compared to a prespecified natural history** cohort of AD.

品牌名称：LEQEMBI®），一种用于治疗早期阿尔茨海默氏病（AD）的抗淀粉样β（Aβ）原纤维*抗体，在西班牙马德里举行的阿尔茨海默氏病临床试验会议（CTAD）上发表。。

There was a 30% reduction in the relative risk of progressing to the next disease stage. In addition, the tau PET substudy of the lecanemab Phase 3 Clarity AD clinical study showed that with three (3) years of continuous treatment with lecanemab, 59% of patients with no or low tau accumulation in the brain (no tau/low tau) at baseline showed improvement or no decline, and 51% showed improvement from baseline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale.1 Clarity AD data presented at CTAD expand on these initial results to include additional measurements resulting from three (3) years of continuous lecanemab treatment in patient.

进展到下一个疾病阶段的相对风险降低了30%。此外，lecanemab 3期Clarity AD临床研究的tau PET亚组研究显示，连续使用lecanemab治疗三（3）年后，59%的患者大脑中没有或低tau积累（无tau/低tau）基线时表现出改善或没有下降，51%的患者在临床痴呆评分框总和（CDR-SB）全球认知和功能量表上显示出比基线有所改善。CTAD提供的Clarity AD数据扩展了这些初始结果，包括三（3）年连续使用lecanemab治疗患者产生的额外测量结果。